These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12154276)

  • 1. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.
    Warlow C
    Stroke; 2002 Aug; 33(8):2137-8. PubMed ID: 12154276
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
    Diener HC
    Stroke; 2002 Aug; 33(8):2138-9. PubMed ID: 12154277
    [No Abstract]   [Full Text] [Related]  

  • 3. Newer antiplatelet therapies in stroke prevention.
    Davis SM; Donnan GA
    Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the best antiplatelet agent for prevention of recurrent stroke in Pakistani patients? Do combinations offer significant advantages in the South Asian context?
    Khan M; Kamal AK
    J Pak Med Assoc; 2010 Sep; 60(9):783-4. PubMed ID: 21381596
    [No Abstract]   [Full Text] [Related]  

  • 5. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA; Newton J; Gray CS
    Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
    [No Abstract]   [Full Text] [Related]  

  • 6. Aspirin therapy should be first line: probably, but watch this space.
    Donnan GA; Davis SM
    Stroke; 2002 Aug; 33(8):2139-40. PubMed ID: 12154278
    [No Abstract]   [Full Text] [Related]  

  • 7. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
    Redman AR; Ryan GJ
    Expert Opin Pharmacother; 2004 Jan; 5(1):117-23. PubMed ID: 14680441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
    Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
    BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Secondary prevention with clopidogrel after TIA or stroke].
    Zuurbier SM; Vermeer SE; Hilkens PH; Algra A; Roos YB
    Ned Tijdschr Geneeskd; 2013; 157(25):A5836. PubMed ID: 23777963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's new in stroke? The top 10 studies of 2006-2008. Part I.
    Hart RG
    Pol Arch Med Wewn; 2008 Nov; 118(11):650-7. PubMed ID: 19140569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy for stroke prevention.
    Hankey GJ
    Curr Atheroscler Rep; 2007 Oct; 9(4):312-8. PubMed ID: 18173959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
    Aw D; Sharma JC
    Postgrad Med J; 2012 Jan; 88(1035):34-7. PubMed ID: 22121248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiplatelet therapy of secondary stroke prevention after ESPS-2 and CAPRIE].
    Alvarez-Sabín J; Montaner-Villalonga J
    Rev Neurol; 1999 Oct 16-31; 29(8):780-4. PubMed ID: 10560115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet therapy in stroke prevention: present and future.
    Caplan LR
    Cerebrovasc Dis; 2006; 21 Suppl 1():1-6. PubMed ID: 16479096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights in antiplatelet therapy for patients with ischemic stroke.
    Chaturvedi S; Bhattacharya P
    Neurologist; 2011 Sep; 17(5):255-62. PubMed ID: 21881467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
    Diener C
    MMW Fortschr Med; 2008 May; 150(21):7. PubMed ID: 18578065
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
    Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R;
    Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.